Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celgene Settlement With Actavis Allows Abraxane Generics In 2022

Jan 27 2018

• By Mandy Jackson

Handshake of businessmen

Related Content

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Celgene to acquire Abraxis Bioscience for $2.9 billion up front

Jun 30 2010

From one billionaire investor to another: NantPharm raises $125 million

Jul 26 2012

Related Companies

Bristol Myers Squibb Company

Teva Pharmaceutical Industries Ltd.

Bristol Myers Squibb Company

NantWorks, LLC

NantWorks, LLC

Cipla Limited

Additional Topics

Intellectual Property Legal Issues Business Strategies Cancer BioPharmaceutical

More from Legal & IP

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window